Humacyte Inc (HUMA)
3.92
-0.17
(-4.16%)
USD |
NASDAQ |
Apr 30, 16:00
3.95
+0.03
(+0.77%)
Pre-Market: 08:16
Humacyte Cash from Operations (TTM): -73.30M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -73.30M |
September 30, 2023 | -73.21M |
June 30, 2023 | -77.01M |
March 31, 2023 | -70.97M |
December 31, 2022 | -71.13M |
Date | Value |
---|---|
September 30, 2022 | -73.62M |
June 30, 2022 | -87.33M |
March 31, 2022 | -85.44M |
December 31, 2021 | -81.19M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-87.33M
Minimum
Jun 2022
-70.97M
Maximum
Mar 2023
-77.02M
Average
-73.62M
Median
Sep 2022
Cash from Operations (TTM) Benchmarks
Adial Pharmaceuticals Inc | -6.807M |
Gritstone Bio Inc | -121.65M |
Precision BioSciences Inc | -84.11M |
Puma Biotechnology Inc | 27.01M |
Revance Therapeutics Inc | -216.58M |